ATNMActinium Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Actinium Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATNM본 종목 | $40M#8 | 3.6x#2 | 1.3x#7 | 443.7x#11 | — | 11.4%#6 | -40274.4%#11 | -111.8%#7 | — | — | -22.8%#1 | — |
| ELTX | $47M#1 | — | 5.9x#12 | 20.2x#8 | -91.9%#8 | 23.8%#4 | -1639.0%#9 | -498.6%#13 | — | — | -84.3%#6 | — |
| HOWL | $46M#2 | — | 2.8x#11 | — | — | 13.7%#5 | — | -373.3%#11 | -229.9%#3 | — | -34.6%#2 | — |
| ANVS | $46M#3 | — | — | — | — | -17.3%#7 | — | — | — | — | -54.8%#4 | — |
| KAPA | $42M#4 | — | 10.1x#13 | — | — | -109.3%#12 | — | -130.0%#9 | — | — | -84.2%#5 | — |
| MCRB | $42M#5 | — | 1.2x#6 | 53.4x#9 | — | 4088.2%#1 | -11910.1%#10 | 16.5%#1 | -72.9%#2 | — | — | — |
| SDEV | $42M#6 | — | 0.3x#1 | 4.3x#6 | -6.4%#5 | -8632.9%#16 | -86.3%#3 | -495.7%#12 | -7.0%#1 | — | — | 11.6%#1 |
| SCYX | $41M#7 | 14.8x#3 | 0.6x#4 | 2.0x#4 | 449.9%#1 | 59.6%#2 | -78.0%#2 | -12.9%#2 | — | 7#1 | — | — |
| VERU | $40M#9 | — | 1.4x#8 | 2.4x#5 | 3.6%#3 | 39.9%#3 | -146.6%#4 | -80.1%#5 | -399.3%#5 | — | -36.3%#3 | 0.0%#2 |
| KPTI | $39M#10 | — | — | 0.3x#1 | 0.6%#4 | -156.5%#13 | -62.1%#1 | — | — | — | — | — |
| ELAB | $38M#11 | — | 2.3x#10 | 64.2x#10 | — | -24.0%#8 | -1304.4%#8 | -46.3%#4 | — | — | -99.7%#7 | — |
| CELU | $37M#12 | — | — | 1.4x#3 | -51.0%#6 | -58.4%#10 | -230.9%#5 | — | -398.1%#4 | — | — | — |
| CRVO | $37M#13 | 0.0x#1 | 1.6x#9 | 9.2x#7 | -58.9%#7 | -65.6%#11 | -706.2%#7 | -117.5%#8 | -5165.9%#6 | — | — | — |
| CNTX | $34M#14 | — | 0.9x#5 | — | — | -35.2%#9 | — | -94.6%#6 | — | — | — | — |
| LITS | $34M#15 | — | 0.6x#3 | — | -100.0%#9 | -189.7%#14 | — | -28.1%#3 | — | — | — | — |
| FLNA | $33M#16 | — | 0.5x#2 | 0.8x#2 | 277.6%#2 | -273.7%#15 | -232.0%#6 | -133.5%#10 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice